The Tokyo-based private company, which has permission since 2014 to prepare in their cell culture processing facilities autologous cultured dermal fibroblast cells for cosmetic purposes, plans to expand her business and apply her know-how to prepare a variety of cells for clinical trials at academia and in pharmaceutical companies.

Nikkei Biotech news release, October 16, 2015